Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
Purpose: To evaluate the safety of intravitreal injection of Stivant, a biosimilar to bevacizumab, in rabbits using electrophysiological and histological analysis.
Methods: Both eyes of 41 New Zealand albino rabbits were injected with 0.1 mL (2.5 mg) of Stivant. The rabbits were scheduled to be sacrificed 1, 2, 7, 14, and 28 days after injection for histopathological evaluations. Clinical examinations and electroretinography (ERG) were performed at baseline and just before sacrificing the rabbits. Fourteen separate rabbits received a reference drug (Avastin) and were considered as the control group. Furthermore, three other rabbits received the same volume of saline (saline control group). Rabbits of both control groups were sacrificed four weeks after injection. ERG was performed 1, 2, 7, 14, and 28 days after injections.
Results: No significant difference was observed in a- and b-wave amplitudes and latency after intravitreal Stivant injection between baseline and different time points. Moreover, there was no statistically significant difference in wave amplitudes and latency between the Stivant and control groups. The histology of rabbit eyes of the Stivant and control groups after intravitreal injections was not distinguishable.
Conclusion: The biosimilar Stivant, up to a dose of 2.5 mg, did not appear to be toxic to the retina in albino rabbits. These results suggest that this drug could be a safe and inexpensive alternative to intravitreal bevacizumab. The efficacy of these injections was not investigated in this study and needs to be evaluated in future studies.
Biosimilar, Intravitreal Injection, Safety, Stivant
1. Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Uchita M, Matsuzaki T, et al. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res 2000;21:655–661.
2. Rezzola S, Nawaz MI, Cancarini A, Semeraro F, Presta M. Vascular Endothelial Growth Factor in the vitreous of proliferative diabetic retinopathy patients: chasing a hiding prey? Diabetes Care 2019;42:e105–e106.
3. Hera R, Keramidas M, Peoc’h M, Mouillon M, Romanet JP, Feige JJ. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol 2005;139:589– 596.
4. Vuletic I, Zhou K, Li H, Bai H, Meng X, Zhu S, et al. Validation of bevacizumab therapy effect on colon cancer subtypes by using whole body imaging in mice. Mol Imaging Biol 2017;19:847–856.
5. Maberley DAL, Zhang R, Ding L, Flatt AH, Etminan M, Hewitt M. One-year effectiveness study of intravitreous bevacizumab in neovascular age-related macular degeneration: a population-based retrospective cohort study. Can J Ophthalmol 2018;53:627–631.
6. Maniadakis N, Konstantakopoulou E. Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review. Pharmacoeconomics 2019;37:995–1010.
7. Sameera V, Apoorva A, Joshi S, Guruprasad A. Safety and efficacy of Razumab – the new biosimilar in India: our experience. Kerala J Ophthalmol 2016;28:180–185.
8. Fenna J, Watkins K, Guirguis M. Biosimilar drugs and the hospital formulary: a Canadian experience. Can J Hosp Pharm 2019;72:145–150.
9. Wang J, Lei C, Tao L, Wu Q, Ke X, Qiu Y, et al. A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits. Sci Rep 2017;7:592.
10. Kampuchea PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102– 1112.e1.
11. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146–2151.
12. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292–2299.
13. Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 update on intravitreal injections: EURETINA expert consensus recommendations. Ophthalmologica 2018;239:181–193.
14. Riazi-Esfahani M, Riazi-Esfahani H, Ahmadraji A, Karkhaneh R, Mahmoudi A, Roohipoor R, et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. Int Ophthalmol 2018;38:585–598.
15. Cho SH, Han S, Ghim JL, Nam MS, Yu S, Park T, et al. A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. BioDrugs 2019;33:173–181.
16. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: ”Is there a big change on the horizon?”. Clin Ophthalmol 2018;12:2137–2143.
17. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257–261.
18. Ziemssen F, Luke M, Messias A, Beutel J, Tatar O, Zrenner E, et al. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2008;28:101–109.
19. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270–274.
20. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res 2002;74:615–625.